Navigation Links
EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
Date:12/4/2007

Multi-Center Study to Focus on Advanced Cancer Patients

ROCKVILLE, Md., Dec. 4 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a multi-center Phase 2 clinical trial with MKC-1 in patients with advanced pancreatic cancer. The primary objectives of this study will be to determine the antitumor activity of orally-administered MKC-1 in unresectable or metastatic pancreatic cancer patients who have failed at least one prior chemotherapy regimen. The study will also assess the safety, tolerability and overall median survival time of pancreatic cancer patients treated with MKC-1. Massachusetts General Hospital Cancer Center is the lead institution for the study and Eunice Kwak, M.D., Ph.D., Assistant in Medicine, Tucker Gosnell Center for Gastrointestinal Cancers, will serve as the principal investigator.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Prior preclinical studies have demonstrated that MKC-1 has significant antitumor activity as both a single agent and in combination with an approved epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) inhibitor in pancreatic cancer models. MKC-1 has also demonstrated broad-acting antitumor effects, including tumor growth inhibition or regression, in multiple preclinical models. MKC-1 has been s
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
6. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
7. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
8. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- Market ... Hydrochloride Industry, 2009-2019 is a professional and ... Oxybutynin Hydrochloride industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Oxybutynin Hydrochloride listing their product ...
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
(Date:9/19/2014)... -- Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia ... an educational program encouraging Hispanics with type 2 diabetes to achieve ... to help reduce the risk of serious health problems. Hispanics in ... risk for developing type 2 diabetes than non-Hispanic white adults, and ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
(Date:9/22/2014)... 2014 One key emerging trend in ... investing in R&D to develop new and advanced biomaterial ... implants. The introduction of third-generation orthopedic biomaterials such as ... will increase the growth of the market in the ... market to grow at a CAGR of 10.78 ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Twix . , ... Twix Unwrapped Bites 7 oz. Stand Up Pouch with specific ... for the recall is that Twix Unwrapped Bites ... contain peanuts and eggs without writing them on the ingredient ...
(Date:9/22/2014)... In CHAMPS Patient Experience's most recent blog ... Summer Meeting , Toya Gorley shares her thoughts on ... The Leader’s Board meeting this summer, which was comprised ... experience to be exhilarating! Many topics were discussed, including:, ... on the patient experience , Technology ...
(Date:9/22/2014)... September 22, 2014 Fancyflyingfox.com, the well-known wedding ... of 2014 plus size wedding dresses . In addition, ... for these fashionable plus size outfits. Each item in the ... up to 65% off. , The company has thousands ... them are now available at extremely affordable prices. Its products ...
(Date:9/21/2014)... cancer patients who smoke, those using e-cigarettes (in addition ... or less likely to have quit smoking traditional cigarettes ... a peer-reviewed journal of the American Cancer Society, the ... for helping cancer patients give up smoking. , Because ... who smoke should be advised to quit. But the ...
Breaking Medicine News(10 mins):Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 2Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 3Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 4Health News:Mars Chocolate North America Recalls Twix Bites: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:CHAMPS' Toya Gorley Discusses the Thought-Provoking Conversation at The Leader’s Board Summer Meeting 2Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2
... a changed version of dopamine// transporter in healthy ... with substance abuse or attention deficit hyperactivity disorder ... the hypothalamus and some areas of the central ... play an important role in hormonal, cardiovascular, renal ...
... is possible to increase the heights of children who ... improved dosages of the growth hormones. ,The researchers ... that the administration of the growth hormone GH-dependent hormone ... (IGF-I) can affect the growth of children in height. ...
... have found out new information about how neuro ... be possibly slowed. ,Researchers at the Rocky ... found novel insights into how abnormal prion proteins ... mice producing prion protein without a glycophosphoinositol (GPI) ...
... be used to detect cancer, says a new study that ... and son research team had been able to bind the ... that will make the tracing of cancer cells much easier. ... factor receptor (EFGR) over their surface. This protein is not ...
... be at less risk from colorectal// cancer. And women who ... B may have even reduced chance of having colorectal cancer. ... of abnormal or malignant cells within the lining of colon ... American researchers, said that inadequate intake of dietary vitamin B ...
... problems// like cognitive impairment in children. ,Researchers across the ... of pollutants like noise from the traffic and aircrafts on ... of 2844 children in the age group of 9 to ... Netherlands, Spain, and UK. Researchers had taken the help of ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: